Your browser is no longer supported. Please, upgrade your browser.
Settings
NCNA NuCana plc daily Stock Chart
NCNA [NASD]
NuCana plc
Index- P/E- EPS (ttm)-0.70 Insider Own15.36% Shs Outstand35.08M Perf Week3.13%
Market Cap254.33M Forward P/E- EPS next Y-0.88 Insider Trans0.00% Shs Float13.08M Perf Month24.36%
Income-22.80M PEG- EPS next Q-0.21 Inst Own33.20% Short Float16.88% Perf Quarter-13.54%
Sales- P/S- EPS this Y40.70% Inst Trans-8.79% Short Ratio38.02 Perf Half Y-38.19%
Book/sh2.86 P/B2.53 EPS next Y-14.00% ROA-21.30% Target Price1250.67 Perf Year-56.87%
Cash/sh2.18 P/C3.32 EPS next 5Y- ROE-23.00% 52W Range4.01 - 19.28 Perf YTD-50.00%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-62.40% Beta-
Dividend %- Quick Ratio13.00 Sales past 5Y- Gross Margin- 52W Low80.80% ATR0.70
Employees24 Current Ratio13.00 Sales Q/Q- Oper. Margin- RSI (14)51.44 Volatility9.16% 11.03%
OptionableNo Debt/Eq0.01 EPS Q/Q-50.00% Profit Margin- Rel Volume1.85 Prev Close7.89
ShortableYes LT Debt/Eq0.00 EarningsNov 26 AMC Payout- Avg Volume58.10K Price7.25
Recom1.50 SMA200.54% SMA505.22% SMA200-30.89% Volume107,455 Change-8.11%
Aug-19-19Initiated H.C. Wainwright Buy $20
Oct-19-18Initiated Piper Jaffray Overweight
Oct-23-17Initiated William Blair Outperform
Oct-23-17Initiated Jefferies Buy $25
Oct-23-17Initiated Citigroup Buy $23
Dec-11-19 07:04AM  New Strong Buy Stocks for December 11th Zacks +7.94%
Nov-27-19 03:32AM  Sorrento Turns Down Two All-Cash Takeover Bids, Stock Jumps Zacks
Nov-26-19 07:00AM  NuCana to Participate in the Piper Jaffray 31st Annual Healthcare Conference GlobeNewswire
Nov-22-19 10:48AM  3 Strong Buy Stocks Set for Triple Digit Gains TipRanks +6.13%
Nov-20-19 09:50AM  Achillion's (ACHN) Danicopan Gets EMA's PRIME Tag for PNH Zacks
Nov-14-19 07:00AM  NuCana to Present at the Jefferies 2019 London Healthcare Conference GlobeNewswire
Nov-13-19 04:01PM  NuCana Reports Third Quarter 2019 Financial Results and Provides Business Update GlobeNewswire
Oct-29-19 07:00AM  NuCana Presents Data at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics GlobeNewswire -5.20%
Oct-25-19 07:00AM  NuCana Announces FDA Clearance to Commence Phase III Study of Acelarin (NUC-1031) for the First-Line Treatment of Patients with Biliary Tract Cancer GlobeNewswire
Oct-17-19 11:24AM  Lilly's Pancreatic Cancer Candidate Fails in Phase III Study Zacks +5.72%
Oct-16-19 12:15PM  Novavax Begins Phase III Study on Influenza Vaccine Candidate Zacks
Sep-20-19 11:12AM  What Percentage Of NuCana plc (NASDAQ:NCNA) Shares Do Insiders Own? Simply Wall St.
Sep-17-19 10:44AM  Seattle Genetics' Enfortumab Vedotin BLA Gets Priority Review Zacks -9.24%
Sep-16-19 08:48AM  Amgen's Kyprolis Combo Improves PFS in Multiple Myeloma Study Zacks
Sep-10-19 06:00PM  FDA Grants Orphan Drug Status to Acceleron's PAH Candidate Zacks
Sep-06-19 10:06AM  NuCana plc (NCNA) Shares March Higher, Can It Continue? Zacks
Sep-03-19 11:00AM  Acorda (ACOR) Down More Than 60% in 3 Months: Here's Why Zacks
Sep-02-19 09:17AM  Akari's Nomacopan Gets Orphan Drug Tag for Rare Disease Zacks
Aug-29-19 08:00AM  NuCana to Present at the Morgan Stanley 17th Annual Global Healthcare Conference GlobeNewswire +7.38%
Aug-27-19 08:00AM  NuCana to Participate in Citis 14th Annual Biotech Conference GlobeNewswire
Aug-21-19 04:01PM  NuCana Reports Second Quarter 2019 Financial Results and Provides Business Update GlobeNewswire
11:08AM  NuCana Stops Patient Enrollment in Pancreatic Cancer Study Zacks
Aug-20-19 11:00AM  NuCana stock falls 21% after company suspends patient enrollment in pancreatic cancer trial MarketWatch +9.29%
08:00AM  Enrollment in the Independent Investigator-Sponsored Phase III Metastatic Pancreatic Study ACELARATE Has Been Suspended Following a Prespecified Futility Analysis GlobeNewswire
Aug-18-19 06:25PM  Analysts Recommend These 2 Falling Knives GuruFocus.com
Jul-18-19 11:18AM  NuCana Initiates Dosing in Phase I Study for Solid Tumors Zacks
Jul-17-19 07:00AM  NuCana Announces First Patients Dosed in Phase I Study of NUC-7738 GlobeNewswire
Jun-13-19 10:26AM  NuCana's Biliary Tract Cancer Candidate Gets Orphan Drug Tag Zacks
07:44AM  The Daily Biotech Pulse: Savara Slumps On Flunked Trial, NuCana Takes Off, Tetraphase Downsizes Benzinga
Jun-12-19 07:24PM  NuCana Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Acelarin® for the Treatment of Biliary Tract Cancer GlobeNewswire
May-30-19 04:01PM  NuCana to Present at the Jefferies 2019 Healthcare Conference GlobeNewswire
May-14-19 04:01PM  NuCana Reports First Quarter 2019 Financial Results and Provides Business Update GlobeNewswire
Apr-02-19 08:00AM  NuCana to Participate in the William Blair 3rd Late-Stage Therapeutics Conference GlobeNewswire
Mar-30-19 10:27AM  Introducing NuCana (NASDAQ:NCNA), The Stock That Dropped 10% In The Last Year Simply Wall St.
Mar-18-19 06:28AM  Will NuCana Continue to Surge Higher? Zacks
Mar-07-19 04:01PM  NuCana Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Business Update GlobeNewswire
Mar-05-19 08:00AM  NuCana to Present at the Cowen and Company 39th Annual Health Care Conference GlobeNewswire
Feb-27-19 04:45PM  NuCana to Present at the American Association for Cancer Research (AACR) Annual Meeting 2019 GlobeNewswire
Jan-25-19 08:32AM  NuCana's stock soars after withdrawing ADS offering, which triggered a big selloff MarketWatch +7.36%
08:15AM  NuCana plc Announces Withdrawal of Public Offering of ADSs GlobeNewswire
Jan-23-19 04:01PM  NuCana plc Announces Proposed Public Offering of ADSs GlobeNewswire
Jan-07-19 10:06AM  Amarin Down on Lower '19 View, Posts Preliminary '18 Results Zacks
Nov-28-18 04:01PM  NuCana to Participate in Citi's 2018 Global Healthcare Conference GlobeNewswire
Nov-27-18 04:01PM  NuCana Reports Third Quarter 2018 Financial Results and Provides Business Update GlobeNewswire
Nov-20-18 07:00AM  NuCana to Participate in the 2018 Evercore ISI HealthCONx Conference GlobeNewswire
Nov-07-18 07:00AM  NuCana to Participate in the Jefferies 2018 London Healthcare Conference GlobeNewswire -8.26%
Nov-01-18 07:00AM  NuCana Announces First Patients Enrolled in Phase Ib Study of NUC-3373 in Advanced Colorectal Cancer GlobeNewswire
Oct-24-18 05:30AM  NuCana Sees Hammer Chart Pattern: Time to Buy? Zacks
Oct-22-18 07:00AM  NuCana Presents Data from Phase I Study of NUC-3373 at ESMO 2018 GlobeNewswire -10.84%
Oct-21-18 06:54AM  NuCana Reports Additional Promising Clinical Data on NUC-1031 (Acelarin®) as Front-Line Treatment of Advanced Biliary Tract Cancer at ESMO 2018 GlobeNewswire
Oct-09-18 01:15PM  NuCana to Present New Data from its ProTide Portfolio at the European Society for Medical Oncology (ESMO) 2018 Congress GlobeNewswire
Aug-29-18 04:01PM  NuCana to Participate in Citis 13th Annual Biotech Conference GlobeNewswire -5.46%
Aug-28-18 04:01PM  NuCana Reports Second Quarter 2018 Financial Results and Provides Business Update GlobeNewswire
Jun-01-18 11:08AM  Better Know Biotech: 2 Stocks You've Got to Know About Motley Fool
May-25-18 04:01PM  NuCana to Participate in the Jefferies 2018 Global Healthcare Conference GlobeNewswire
May-23-18 04:02PM  NuCana Reports First Quarter 2018 Financial Results GlobeNewswire
May-21-18 07:01AM  NuCana Announces Appointment of Cyrille Leperlier to its Board of Directors GlobeNewswire +11.94%
07:00AM  NuCana Announces Appointment of Cyrille Leperlier to its Board of Directors GlobeNewswire
May-17-18 07:00AM  NuCana CEO Hugh Griffith Honored with the Outstanding Achievement Award from Life Sciences Scotland GlobeNewswire
Apr-09-18 07:01AM  NuCana plc Announces Appointment of Adam George to its Board of Directors GlobeNewswire
07:00AM  NuCana plc Announces Appointment of Adam George to its Board of Directors GlobeNewswire
Mar-21-18 04:09PM  NuCana Reports Financial Results for the Year Ended December 31, 2017 GlobeNewswire
Mar-02-18 08:01AM  NuCana plc to Participate in the Cowen and Company 38th Annual Health Care Conference GlobeNewswire
08:00AM  NuCana plc to Participate in the Cowen and Company 38th Annual Health Care Conference GlobeNewswire
Jan-23-18 07:00AM  Wired News NuCana Announced Positive Results from Clinical Data on Acelarin® as Front-Line Treatment of Advanced Biliary Tract Cancer at ASCO GI 2018 ACCESSWIRE
Jan-22-18 09:59AM  Heres Whats Moving NuCana plc (NASDAQ:NCNA) and PHARMA MAR (OTCMKTS:PHMMF) Market Exclusive +6.29%
Jan-19-18 12:02PM  NuCana Announces Promising Clinical Data at ASCO GI on NUC-1031 (Acelarin®) as Front-Line Treatment of Advanced Biliary Tract Cancer GlobeNewswire +41.55%
Nov-20-17 08:02AM  NuCana plc to Participate in the Evercore ISI Biopharma Catalyst / Deep Dive Conference GlobeNewswire
Nov-15-17 08:01AM  NuCana Announces First Patients Enrolled in Phase 2 Study of Acelarin in Platinum-Resistant Ovarian Cancer GlobeNewswire
Nov-02-17 08:00AM  NuCana plc to Present at the Jefferies 2017 London Healthcare Conference GlobeNewswire
Oct-23-17 02:16PM  Analysts See Potential In The NuCana Pipeline Benzinga
Oct-02-17 02:28PM  NuCana plc Announces Closing of Initial Public Offering of ADSs and Exercise of Underwriters' Option to Purchase Additional ADSs GlobeNewswire
01:40PM  NuCana plc Announces Closing of Initial Public Offering of ADSs and Exercise of Underwriters Option to Purchase Additional ADSs GlobeNewswire
Oct-01-17 09:43AM  IPO News This Week: Data Center Firm Switch Tops a Short List 24/7 Wall St.
Sep-27-17 09:36PM  NuCana plc Announces Pricing of Initial Public Offering GlobeNewswire
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. It is developing Acelarin that is in Phase I clinical trials for the treatment of advanced metastatic solid tumors; Phase Ib clinical trials for the treatment of recurrent ovarian cancer; Phase II clinical trials for the treatment of patients with platinum-resistant ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary cancer; and Phase III clinical trials for the treatment of pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors; and NUC-7738, a nucleoside analog that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.